Saturday, December 24, 2011
Presentations Highlight Results Of Clinical Data For MLN8237 And VELCADE� In The Treatment Of Lymphoma
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) reported the presentation of results from a phase 2 trial evaluating MLN8237, an investigational inhibitor of Aurora A kinase, in patients with aggressive B-cell and T-cell non-Hodgkin lymphoma (NHL). Also presented were biomarker data from a phase 3 study comparing VELCADE� (bortezomib) and rituximab (VcR) to rituximab (R) alone in patients with relapsed or refractory follicular lymphoma (FL)...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment